We identified a high prevalence of SOR (n = 72; 49.7%) in NSPT trials. Further, our results showed an association of SOR with statistical significance of the primary outcome in the publication, and more than one publication resulting from the same study.
The high prevalence of SOR in the NSPT trials is similar to those observed in the medical field: 62% in the study by Chan et al. [8] and 49% both in surgical trials [18] and hematology publications [19]. In Dentistry, the prevalence was also high: 47% in the orthodontics field [20], 55.1% in dental implant studies [16], and 40.9% in root coverage trials [12]. Despite this high rate, the prevalence of SOR may have been underestimated for two reasons: 1) SOR was unclear in almost a third of the studies (n = 40; 27.6%) because authors did not specify the primary outcome in the publication; 2) we only used the www.clinicaltrials.gov platform to identify the protocols. Therefore, extending the search to other platforms could have increased SOR occurrence.
Most of the analyzed protocols (91.7%) were retrospectively recorded. This is a concerning result because late registration allows authors to change their outcomes once they have analyzed data. Retrospective registration creates room for publication bias and changes in the pre-specified primary outcome [21]. The rates of retrospective registration range from 46.9–79% in studies from the medical and dental fields [12, 16, 21, 22]. Study registration alone is not enough to increase transparency in reporting; it must be carried out prospectively before the inclusion of the first study participant [21, 23, 24].
Our study identified the primary outcome in 81.4% of the analyzed publications. A systematic review examining periodontal trials' primary outcomes between 2018 and 2020 showed that only half of the publications (54%) identified the primary outcome [25]. The low number of publications that identified the primary outcome is worrisome, since this oversight may increase the probability of authors selecting positive results, or omitting inconvenient results [26].
We analyzed the complete definition of the primary outcome both in the protocols and in their associated publications. According to the five specification levels, only 5.6% of the protocols had a completely specified outcome. A recent medical study also observed that the primary outcome was completely defined in only 3.3% of the trials, considering the five specification levels [27]. This percentage rose to 29.6% when we disregarded the aggregation method of the analysis. We carried out both analyses because in many studies, researchers only define the aggregation method in the statistical analysis after obtaining data and checking for normality and homoscedasticity [11]. On the other hand, we observed that almost a third (31.7%) of the publications presented the complete specification of the outcome when considering the five levels. After excluding the aggregation method from the analysis, this number increased to 35.5%. In a previous publication [12] we also observed a low rate (22.7%) of completely defined outcomes.
We did not identify an association between SOR and incomplete specification of the primary outcome in protocol and publication (p > 0.05). In contrast, Sendyk et al. [12] showed an association of SOR with an unclear definition of the primary outcome in the publication. Although no significant association was observed, it is worth noting observationally that there was SOR in 56.2% of the studies with an unclear definition of the outcome, as compared to 32.5% of the studies with a completely defined outcome. A possible explanation for this trend is that incomplete definition of the outcome can lead to cherry-picking, i.e., the investigator can perform multiple statistical analyses and select only the specific measures, metrics, or time points of the outcome that are statistically significant [13, 26]. These results emphasize the need to improve the description of the outcome, both in the protocol and in the publication.
Of the 145 included studies, 13 resulted in more than one publication referring to the same research protocol. Of these, 92.3% presented SOR. We observed SOR in the companion papers of these studies (i.e., from the second publication onwards). In these cases, the authors often 1) included a new primary outcome, 2) promoted the protocol's secondary outcome to the primary, or 3) omitted the protocol's primary outcome, recalculating the sample size for the outcome of interest. As a result, we observed a significant association between multiple publications and SOR. To prevent SOR and ensure transparency, authors must select a priori one primary outcome for the study and register this outcome in a publicly accessible registry. All resulting publications should mention the same original outcome as the primary [25], even in cases of companion papers that emphasize secondary outcomes.
SOR was associated with statistical significance, supporting previous findings [7, 8, 12, 19, 21, 28, 29]. The intention to select significant results to increase the chances of publication may be one of the reasons for the occurrence of SOR [8, 28, 30]. Furthermore, studies that interviewed authors to identify the reasons for the occurrence of SOR showed that the main justifications were a) lack of clinical importance, b) lack of statistical significance and c) space restrictions in the publication [8, 31, 32]. These findings corroborate Smyth et al. [33], who also demonstrated that there is misinformation by the authors, who do not understand the importance and consequences of not reporting all results in building the body of evidence. Omitting a non-significant finding or introducing a significant result can lead to overestimating the effectiveness of treatments and interfering with clinical practice [9, 10, 28, 34].
One of the limitations of this investigation is that the protocol search strategy was restricted to the www.clinicaltrials.gov platform, which may have compromised the external validity of our research. On the other hand, other registration platforms do not have the "history of changes" tool that identifies any changes made to the research protocol after its registration. Therefore, we chose to use www.clinicaltrials.gov because of the possibility of analyzing these changes.
Some measures can improve reporting transparency and reduce the incidence of SOR, such as 1) prospective registration of the study before the inclusion of the first research patient; 2) the complete definition of the primary outcome both in the research protocol and in the final publication; 3) changes in the planning and conduct of the ECR informed appropriately and transparently. In addition, journal editors should instruct reviewers to check for discrepancies between the protocol and the manuscript whenever such information is available. These efforts can increase the transparency of clinical trials, strengthening evidence-based practice in Periodontology and other fields of dentistry.